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Background: Pancreatic enzyme replacement therapy is the foundation of nutritional management for exocrine pancreatic insufﬁciency (EPI).
Methods: A 3-month, open-label, multicentre study in Russia assessing safety, efﬁcacy, and ease-of-use of Creon® Micro (5000 lipase units/spoon)
in children aged 1 month to b4 years with EPI due to cystic ﬁbrosis. Efﬁcacy assessments included growth parameters.
Results: All 40 subjects (mean age 26.5 months) completed treatment. Adverse events occurred in 40% of the subjects (most commonly respiratory
tract infection [15%], frequent bowel movements [8%], rhinitis, stomatitis, nasopharyngitis, and diarrhoea [all 5%]), none were serious or led to
discontinuation. After 3 months, mean ± SD increases from baseline z-scores were height/length-for-age 0.13 ± 0.48, weight-for-age 0.20 ± 0.39,
and BMI-for-age 0.29 ± 0.65. Treatment was rated ‘easy’ to administer by 95% caregivers and acceptance ‘good’/‘very good’ by 90%.
Conclusions: Creon Micro was well tolerated. Growth development parameters increased over the 3-month treatment period. Treatment was
considered easy to use and acceptance was good.
© 2014 European Cystic Fibrosis Society. Published by Elsevier B.V. Open access under CC BY-NC-ND license.Keywords: Clinical trial; Creon; Cystic ﬁbrosis; Pancreatic enzyme replacement therapy; Exocrine pancreatic insufﬁciency; Pancreatin1. Introduction
Exocrine pancreatic insufficiency (EPI) affects approximately
80–90% patients with cystic fibrosis (CF). It is often present at
birth and is identified in the majority of patients within their first
year [1–3]. EPI results in the maldigestion of food and
malabsorption of nutrients, including fat soluble vitamins,
leading to malnutrition and symptoms such as poor weight
gain, steatorrhea, and abdominal pain [4]. Several studies have
shown that adequate nutrition and normal growth are associated☆ Trial registration: clinicaltrials.gov NCT01747330.
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increased survival in patients with CF [5–10]. If EPI is untreated
or undertreated, poor growth and development is likely to
adversely affect disease course and survival. Early diagnosis of
CF, and early detection and treatment of EPI, is therefore vital. In
Russia, children with CF are now detected mainly through the
national neonatal screening program, initiated in January 2007,
which facilitates early diagnosis and treatment.
The standard of care for EPI is pancreatic enzyme
replacement therapy (PERT) in combination with dietary
management, regardless of its aetiology. Guidelines for the
management of CF include the use of PERT for the treatment of
EPI [10–12]. Creon® (pancreatin; Abbott Laboratories GmbH,
Hannover, Germany) is a PERT indicated for the treatment of
EPI due to CF, chronic pancreatitis, pancreatectomy, or other
conditions, and is available in several different formulations
worldwide. Creon®Micro (pancreatin gastro-resistant granules inpen access under CC BY-NC-ND license.
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particular for infants and young children to allow accurate dosing
in those who require lower doses or are unable to swallow
capsules. Each 100 mg of gastro-resistant granules (equivalent
to one measuring spoonful) contains 60.12 mg of pancreatin,
which contains the following pancreatic enzymes: lipase
5000 Ph. Eur. units, amylase 3600 Ph. Eur. units, and protease
200 Ph. Eur. units [13]. Clinical trials have demonstrated the
efficacy and safety of Creon Micro in infants and young children
[14,15] and Creon Minimicrospheres capsules in children
b7 years [16] and 7–11 years [17] with EPI due to CF. This
prospective, open-label, multicentre study was carried out in
Russia for compliance with local regulatory requirements, and its
objective was to assess the safety, efficacy, and ease-of-use of
Creon Micro in children with EPI due to CF.
2. Methods
This was a prospective, open-label, multicentre study
comprising a screening period, a baseline assessment ≤14 days
after screening, a 3-month treatment period (starting on Day 1),
and a safety follow-up phone call 30 + 3 days after end of
treatment. The study was carried out at eight centres in Russia
between June and December 2012 (clinicaltrials.gov identifier
NCT01747330) and was conducted in accordance with the EU
Clinical Trial Directive, the International Conference on
Harmonization guideline for Good Clinical Practice, and the
principles of the Declaration of Helsinki. The study protocol and
informed consent form were approved by an Independent Ethics
Committee that complied with local regulatory requirements.
Voluntary written informed consent was provided by the caregiver
(or a legally acceptable representative) prior to performing any
study-related procedures.
2.1. Participants
Participants were enrolled by the study investigators. Males
and females aged 1 month to b4 years with a confirmed CF
diagnosis and EPI were eligible for inclusion. CF diagnosis was
confirmed by pilocarpine iontophoresis (chloride concentration
≥60 mmol/L) or sweat conductivity testing [18] (Macroduct®/
Nanoduct® conductivity ≥80 mmol/L sodium chloride equiva-
lents) and/or a genotype with two identifiable mutations consistent
with CF accompanied by one or more clinical features of the
CF phenotype. EPI was determined by a faecal elastase-1 level
b100 μg/g stool. Subjects were also required to have a body
weight of at least 2 kg and a clinically stable condition without
evidence of acute respiratory disease or any other acute condition.
Key exclusion criteria were: surgery due to meconium ileus with
intestinal resection; history of fibrosing colonopathy, distal
intestinal obstruction syndrome or acute abdomen; solid organ
transplant or surgery affecting the large bowel (excluding
appendectomy), or small bowel surgery that significantly affected
absorptive capacity; use of immunosuppressive drugs except
steroids; any type of malignancy involving the digestive tract;
known allergy to pancreatin or inactive ingredients of treatment;
intake of experimental drug within 30 days prior to study start;subjects on parenteral or enteral nutrition; any clinically relevant
disease that could limit participation in or completion of the
study.
Use of other PERT preparations, narcotic analgesics, anti-
diarrhoeals, antispasmodics, and laxatives during the study was
prohibited, but medications influencing duodenal pH, gastric
emptying, and bile secretion were permitted if taken at a stable
dose.
Subjects were categorized as infants and toddlers (b2 years)
or children (≥2 years) based on their age at screening according
to the European Medicines Agency age classification [19].
2.2. Treatment
If applicable, subjects received their previously-prescribed
PERT at the usual dose until start of treatment with Creon
Micro. During the study, Creon Micro was administered at a
dose of 5000 lipase units per 120 mL of formula or breast feed,
or 1000 lipase units/kg body weight/meal, according to the
Cystic Fibrosis Foundation guidelines [12,20]. The minimum
dose was 5000 units/meal, corresponding with one spoon of
Creon Micro (100 mg), and increased if needed in increments
of 5000 lipase units/meal. The maximum dose permitted was
2500 units/kg bodyweight per feeding, or 4000 units/g fat intake,
or 10,000 lipase units/kg body weight/day [11,12]. Caregivers
were instructed to give Creon Micro during or immediately after
meals with liquid (pH b 5.5) or by adding it to small amounts
of acidic soft food (pH b 5.5) that did not require chewing
(e.g., applesauce), which was to be swallowed immediately and
followed with water or juice to ensure complete ingestion.
Caregivers were also asked to ensure that no drug was retained in
the mouth.
2.3. Safety
Safety was assessed by monitoring adverse events (AEs).
AEs were recorded by investigators using standard medical
terminology and then coded according to the Medical Dictionary
for Regulatory Activities version 15.1. The severity of AEs, their
likely relationship to study drug (unrelated, unlikely, possible,
probable), related changes in study medication, outcome, and
whether serious or not were also recorded.
Other safety assessments including physical examination, vital
signs, and laboratory safety tests were performed. Blood samples
were analyzed at Laboratory INVITRO, Moscow, Russia.
2.4. Efficacy assessments
Efficacy was evaluated by assessing the growth parameters of
height/length and bodyweight at baseline,Month 1, andMonth 3.
To assess development relative to a standard population, height/
length-for-age, weight-for-age, and BMI-for-age percentiles and
z-scores were calculated by comparison with the respective age
and gender-specific percentiles of the US population published by
the Centers for Disease Control and Prevention in 2000 [21]. The
US population was used as specific percentiles for the Russian
paediatric population are not available. The clinical symptoms of
Table 1
Subject characteristics and medical history at baseline (safety sample).
b2 years
(n = 21)
2–3 years
(n = 19)
All subjects
(n = 40)
Age in months
Mean ± SD 14.8 ± 6.7 39.4 ± 6.9 26.5 ± 14.1
Median 16.0 40.0 23.0
Range 1.0–23.0 25.0–47.0 1.0–47.0
Male, n (%) 14 (66.7) 13 (68.4) 27 (67.5)
Race white, n (%) 21 (100.0) 19 (100.0) 40 (100.0)
Height/length in m, mean ± SD 0.8 ± 0.1 1.0 ± 0.1 0.9 ± 0.1
Weight in kg, mean ± SD 9.9 ± 2.2 13.9 ± 2.3 11.8 ± 3.0
Most frequent medical history, a %
Bronchitis/chronic bronchitis 42.8 57.9 50.0
Anaemia 42.9 15.8 30.0
Pseudo-Bartter's syndrome 28.6 10.5 20.0
a Preferred terms; all subjects had exocrine pancreatic insufficiency.
Table 2
Summary of adverse events (safety sample).
b2 years
(n = 21)
2–3 years
(n = 19)
All subjects
(n = 40)
At least one AE, n (%) 11 (52.4) 5 (26.3) 16 (40.0)
At least one serious AE, n (%) 0 0 0
AEs possibly/probably related to
treatment, n (%)
2 (9.5) 3 (15.8) 5 (12.5) a
AEs leading to discontinuation, n (%) 0 0 0
All AEs, n (%)
Respiratory tract infection 3 (14.3) 3 (15.8) 6 (15.0)
Frequent bowel movements 0 (0.0) 3 (15.8) 3 (7.5)
Rhinitis 2 (9.5) 0 (0.0) 2 (5.0)
Stomatitis 2 (9.5) 0 (0.0) 2 (5.0)
Nasopharyngitis 1 (4.8) 1 (5.3) 2 (5.0)
Diarrhoea 1 (4.8) 1 (5.3) 2 (5.0)
Ear infection 1 (4.8) 0 (0.0) 1 (2.5)
Otitis media (acute) 0 (0.0) 1 (5.3) 1 (2.5)
Anal fissure 0 (0.0) 1 (5.3) 1 (2.5)
Teething 1 (4.8) 0 (0.0) 1 (2.5)
Abdominal pain (upper) 1 (4.8) 0 (0.0) 1 (2.5)
Steatorrhoea 0 (0.0) 1 (5.3) 1 (2.5)
Anaemia 0 (0.0) 1 (5.3) 1 (2.5)
Chalazion 0 (0.0) 1 (5.3) 1 (2.5)
Food allergy 0 (0.0) 1 (5.3) 1 (2.5)
Balanitis 1 (4.8) 0 (0.0) 1 (2.5)
Cough 1 (4.8) 0 (0.0) 1 (2.5)
AE: adverse event.
a Five subjects experienced 6 AEs considered ‘possibly’ treatment-related by
the investigator.
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and watery) were recorded in a daily diary by caregivers. The
average daily stool frequency during treatment was calculated
(only days with a recorded stool frequency were taken into
account). The percentage of days with each stool consistency was
calculated relative to the total number of days with recordings
during treatment. For subjects with more than one stool category
recorded on one day, that day was evenly weighted for the
respective categories.
2.5. Acceptance of treatment and ease-of-use
Caregivers assessed the subjects' acceptance of treatment at
Month 1 and Month 3 using the following scale: very good,
good, moderate, or unsatisfactory. In addition, at Month 3,
caregivers provided their opinion on ease-of-use, based on the
ease of dosing using the spoon provided: easy or difficult. For
subjects who had received PERT before this study, the caregiver
was also asked to rate the ease-of-use of Creon Micro compared
with previous capsule treatment: easier than capsule therapy, the
same as capsule therapy, or harder than capsule therapy.
2.6. Statistics
Safety analyses were performed using the safety sample,
defined as all subjects who consented and received at least one
dose of study medication. Efficacy analyses were performed on
the full analysis sample, defined as all subjects in the safety
sample who had data for at least one post-baseline assessment
of any efficacy measurement. Summary statistics are provided
for safety and efficacy outcomes for the overall population and
by age group: b2 years and 2–3 years (because subjects were
required to be b4 years of age there were no subjects aged 4,
therefore the latter group is reported as 2–3 years not 2–4 years).
As this was an exploratory study, significance was not tested.
3. Results
3.1. Patient disposition and characteristics
All 40 subjects enrolled completed the study; there were
21 subjects aged b2 years and 19 subjects aged 2–3 years.
Demographic characteristics are summarized in Table 1. As
expected, there were differences between the two age subgroups
in age, height, and weight. A history of anaemia and Pseudo-
Bartter's syndrome was reported more frequently in younger
subjects, and bronchitis/chronic bronchitis was reported more
frequently in older subjects.
All subjects used concomitant medications after start of
study treatment. The most frequently used were expectorants
excluding combinations with cough suppressants (e.g., dornase
alfa ± acetylcysteine ± ambroxol hydrochloride; 95.2% of sub-
jects in the b2 years group and 100% of subjects in the 2–3 years
group), bile therapy (66.7% and 100%, respectively), adrenergic
inhalants (28.6% and 42.1%, respectively), and vitamins A and
D, including combinations of the two (33.3% and 26.3%,
respectively).3.2. Safety
The duration of exposure to Creon Micro ranged from 74 to
93 days and the individual median lipase dose ranged from
3636 to 12,500 lipase units/kg body weight/day. Three subjects
exceeded the recommended maximum dose (10,417, 10,378,
and 12,500 lipase units/kg body weight/day); all were in the
b2 years age group.
AEs are summarized in Table 2. There were no cases
suggestive of fibrosing colonopathy during the study. The six
AEs considered ‘possibly’ treatment-related by the investigator
were: b2 years age group— stomatitis (n = 1), upper abdominal
Fig. 1. Stool consistency during the 3-month treatment period (full analysis
sample).
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(n = 2), anal fissure (n = 1), and steatorrhoea (n = 1). No AE
was judged ‘probably’ related to treatment.
No relevant changes were observed overall in laboratory
parameters and there were no safety concerns with respect to
laboratory parameters and vital signs.
3.3. Efficacy
In the overall population, changes from baseline after
3 months were observed in height/length (mean ± SD change
0.03 ± 0.02 m), weight (0.75 ± 0.61 kg), height/length-for-age
(2.78 ± 12.87 percentile points; z-score 0.13 ± 0.48), weight-for-
age (4.14 ± 9.42 percentile points; z-score 0.20 ± 0.39) and BMI-
for-age (7.71 ± 17.98 percentile points; z-score 0.29 ± 0.65).
Changes by age subgroup are shown in Table 3. During Creon
Micro treatment, the mean ± SD daily stool frequency was
2.1 ± 0.8 in the overall population, 2.2 ± 0.6 in patients b2 years
and 1.8 ± 0.9 in those 2–3 years. The mean percentage of days
without soft or watery stools was 64.8% in the overall population.
Stool consistency data by age subgroup are shown in Fig. 1.
3.4. Acceptance of treatment and ease-of-use
After 3 months, treatment acceptance was judged ‘good’ or
‘very good’ by 90%of caregivers overall, rated ‘easy’ to administer
by 95%, and rated ‘easier to use’ or ‘the same as’ previous capsule
PERT by 83%. Data by age group are shown in Fig. 2. Ease-of-use
and treatment acceptance were slightly better in the b2 years
subgroup compared with the 2–3 years subgroup.Table 3
Change from baseline to end of 3-month treatment phase in growth parameters (full
b2 years (n = 21)
Baseline Change from baselin
Height/length in m, mean ± SD 0.77 ± 0.09 0.04 ± 0.02
Weight in kg, mean ± SD 9.89 ± 2.24 0.90 ± 0.64
Height/length-for-age a
Percentile
Mean ± SD 38.90 ± 26.26 6.53 ± 13.89
Median 36.92 5.65
Z-score
Mean ± SD −0.46 ± 1.11 0.27 ± 0.56
Median −0.33 0.34
Weight-for-age a
Percentile
Mean ± SD 32.09 ± 28.98 5.65 ± 10.67
Median 19.69 3.40
Z-score
Mean ± SD −0.68 ± 1.11 0.22 ± 0.36
Median −0.85 0.29
BMI-for-age a,b
Percentile
Mean ± SD – –
Median – –
Z-score
Mean ± SD – –
Median – –
a Calculated by comparison with the respective age and gender-specific percentile
b BMI growth percentiles are not available for infants b2 years of age.4. Discussion
PERT, in combination with dietary management, is the
standard of care for the treatment or prevention of malnutrition
in patients with EPI. In this open-label study, Creon Micro was
well tolerated with a favourable safety profile in young children
with EPI due to CF. There were no serious AEs or AEs leading
to discontinuation. Of the most frequent AEs, respiratory tract
infection, frequent bowel movements, and rhinitis are known
complications of CF, and stomatitis can be a local side effect of
prolonged retention of PERT in the mouth [13], or related to
vitamin B or iron deficiency [22,23]. The number of AEs
judged to be possibly related to treatment was low, and those ofanalysis sample).
2–3 years (n = 19)
e at 3 months Baseline Change from baseline at 3 months
0.95 ± 0.07 0.01 ± 0.01
13.88 ± 2.25 0.59 ± 0.55
37.69 ± 30.08 −1.38 ± 10.49
36.30 −0.74
−0.49 ± 1.22 −0.02 ± 0.33
−0.35 −0.04
32.05 ± 25.42 2.47 ± 7.76
30.94 0.43
−0.75 ± 1.17 0.17 ± 0.42
−0.50 0.02
32.04 ± 28.48 7.71 ± 17.98
21.54 5.87
−0.60 ± 1.04 0.29 ± 0.65
−0.79 0.27
s of the US population [21].
AB
C
Fig. 2. Caregiver assessment of treatment acceptance (A), ease-of-use (B) and
ease-of-use compared with previous therapy (C) at the end of the 3-month
treatment period (full analysis sample).
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known adverse drug reactions associated with Creon treatment
[13]. These safety findings compare favourably with other studies
assessing Creon in subjects with EPI due to CF, including two
studies of Creon Micro in paediatric subjects that had shorter
treatment periods of 2 weeks [15] and 8 weeks [14] (overall
frequency of AEs 43.6% and 75%, respectively; frequency of
treatment-related AEs 7.7% and 8.3%, respectively), and a study
of Creon capsules in children b7 years old with a treatment
period of ~2 weeks (overall AEs 50%; treatment-related AEs
5.6%) [16]. Although three patients exceeded the highest
recommended dose of 10,000 lipase units/kg body weight/day,no cases suggestive of fibrosing colonopathy or other serious
events occurred in these patients. Two of these patients
experienced AEs, which were stomatitis (judged ‘unrelated to
treatment’) and diarrhoea (judged ‘unlikely related to treatment’).
In terms of efficacy, subjects aged b2 years displayed an
increase in height, weight, and height/weight-for-age over the
3-month treatment period. Subjects aged 2–3 years also showed
an increase in these growth parameters, as well as BMI-for-age,
although the increases were smaller than in the younger age
group, and a slight decrease was observed in height-for-age in
this group. Stool frequency observed during treatment was within
the range seen in other studies of young children with CF
receiving PERT (1.8–2.4 per day) [14–16,24] and similar to that
found in surveys of healthy children aged 1 to 4 years in the UK
(1–2 per day) [25] and aged 1 month to 3 years in Italy (1.4–1.9
per day) [26]. The mean percentage of days without soft/watery
stools during treatment in our study (65%), compares favourably
with other studies of Creon in young children (N48% days
without soft/watery stools [15] and approximately 60–70%
patients without soft/watery stools each day [16]).
The slight decrease in standardized height in the 2–3 years
subgroup may be a result of minor height fluctuations during the
day and difficulties in measuring height in mobile paediatric
subjects. In addition, the study duration of 3 months is a relatively
short treatment period for the measurement of changes in growth
parameters; a longer study duration would have been desirable.
Furthermore, differences in growth parameters between subjects
with CF and healthy children are expected. In both age subgroups,
the median baseline height-for-age was below the 40th percentile
(Table 3). The median baseline weight-for-age was below the
20th percentile in the b2 years group, and below the 35th
percentile in the 2–3 years group (Table 3).
The majority of caregivers indicated that Creon Micro was
‘easy’ to use and that patient acceptance of treatment was
‘good’ or ‘very good’. Most caregivers also considered Creon
Micro to be easier to use or the same as previous capsule PERT,
with greater benefit in using this formulation seen in younger
subjects compared with older subjects. These findings indicate
that Creon Micro is an age-appropriate formulation with
benefits for young children over standard capsule formulations.
The main study limitations are the open-label design and the
lack of placebo/control group or run-in period on placebo/
without treatment; this design was selected for ethical reasons.
In addition, as mentioned above, the duration of the study was
relatively short for the measurement of changes in growth
parameters such as height and weight, as only small increases
would be expected over this period, even in young children. Other
limitations include the inability to measure clinical symptoms at
baseline owing to the use of different PERT formulations and
doses prior to study start, and the lack of a direct measurement of
efficacy (e.g., changes in fat absorption). Although the population
enrolled here was a paediatric population, the safety and efficacy
results are likely generalisable to all patients with CF and EPI who
require PERT.
In this open-label study, Creon Micro was well tolerated with
a favourable safety profile when administered at doses recom-
mended by International Guidelines [11,12,20]. Increases were
280 N.Y. Kashirskaya et al. / Journal of Cystic Fibrosis 14 (2015) 275–281observed in growth parameters over the 3-month treatment
period, and Creon Micro was well accepted by subjects and
considered easy-to-use by caregivers. These findings strengthen
the existing evidence that Creon is effective in the treatment of
EPI, with a consistent safety profile. Creon Micro is an age-
appropriate paediatric formulation, as demonstrated by the
acceptance and ease-of-use evaluation, particularly for children
below 2 years of age.Funding statement
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